A different engagement profile
The development thesis is assembly inhibition that persists as free drug concentrations fall. Laboratory studies will determine whether that profile can be achieved with useful selectivity and exposure.
Defined candidates and a focused next step
BioTwin has helped us compare molecular designs, examine recognition, reaction chemistry and exposure, and prepare a draft experimental verification plan. We have defined lead and alternative designs, with synthesis and laboratory evaluation as the next stage.
A development and licensing opportunity
We are seeking a partner to help evaluate and develop the program. We can start with a nonconfidential overview, then agree a mutual CDA and the specific evidence needed for a focused scientific review.
What the clinical result changes
On September 4, 2026, Novartis reported that pelacarsen’s Lp(a)HORIZON trial missed its primary cardiovascular endpoint despite lowering Lp(a). This finding raises questions for future research about intervention, measurement and clinical benefit; it does not establish which alternative mechanism would work.
- Read the sponsor’s topline report · The announcement states that detailed trial data will be presented at a medical congress. Novartis, September 4, 2026